158 related articles for article (PubMed ID: 9689964)
1. [Adjuvant or therapeutic androgen suppression in locoregional advanced prostatic carcinoma (RTOG 85-31)].
Hinkelbein W
Strahlenther Onkol; 1998 Jul; 174(7):385-6. PubMed ID: 9689964
[No Abstract] [Full Text] [Related]
2. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
Pilepich MV; Winter K; Lawton CA; Krisch RE; Wolkov HB; Movsas B; Hug EB; Asbell SO; Grignon D
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1285-90. PubMed ID: 15817329
[TBL] [Abstract][Full Text] [Related]
3. [Integrated (surgical and hormonal) treatment of advanced prostatic carcinoma. Comment on the study and the interview with Edward M. Messing].
Prayer Galetti T
Recenti Prog Med; 2001 Feb; 92(2):126-7. PubMed ID: 11294103
[No Abstract] [Full Text] [Related]
4. Response of cerebral metastasis secondary to prostate cancer to primary androgen suppression.
Bhuva NJ; Ward D; Hughes R
BMJ Case Rep; 2010 Nov; 2010():. PubMed ID: 22789555
[TBL] [Abstract][Full Text] [Related]
5. [Therapy of nodal positive prostatic carcinoma: when should hormone therapy be started?].
Zierhut D
Strahlenther Onkol; 1998 Jul; 174(7):382-3. PubMed ID: 9689961
[No Abstract] [Full Text] [Related]
6. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
Scalliet P
Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815
[No Abstract] [Full Text] [Related]
7. [Reevaluation of MAB therapy and progress of endocrine therapy].
Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
[No Abstract] [Full Text] [Related]
8. [Pro and contra -- adjuvant therapy in locoregional advanced prostatic carcinoma after radical prostatectomy].
Hammerer P
Aktuelle Urol; 2004 Sep; 35(5):371-2. PubMed ID: 15384001
[No Abstract] [Full Text] [Related]
9. [Update of the study on survival with early hormonal therapy associated with radiotherapy (EORTC 22863 Study) in patients with advanced prostatic cancer. Interview with Michel Bolla].
Bolla M
Recenti Prog Med; 2001 Feb; 92(2):128-9. PubMed ID: 11294104
[No Abstract] [Full Text] [Related]
10. Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
Rogers C
J Urol; 2003 Nov; 170(5):1955; author reply 1955-6. PubMed ID: 14575038
[No Abstract] [Full Text] [Related]
11. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
[TBL] [Abstract][Full Text] [Related]
12. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group.
Corn BW; Winter K; Pilepich MV
Urology; 1999 Sep; 54(3):495-502. PubMed ID: 10475361
[TBL] [Abstract][Full Text] [Related]
13. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
Pilepich MV; Caplan R; Byhardt RW; Lawton CA; Gallagher MJ; Mesic JB; Hanks GE; Coughlin CT; Porter A; Shipley WU; Grignon D
J Clin Oncol; 1997 Mar; 15(3):1013-21. PubMed ID: 9060541
[TBL] [Abstract][Full Text] [Related]
15. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?].
Matveev BP; Bukharkin BV
Urologiia; 2003; (6):6-10. PubMed ID: 14708235
[TBL] [Abstract][Full Text] [Related]
16. [Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].
Noël G; Mazeron JJ
Cancer Radiother; 2001 Apr; 5(2):205. PubMed ID: 11355590
[No Abstract] [Full Text] [Related]
17. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer.
Gomella LG; Zeltser I; Valicenti RK
Urology; 2003 Dec; 62 Suppl 1():46-54. PubMed ID: 14747041
[TBL] [Abstract][Full Text] [Related]
18. RTOG study shows improved survival for prostate cancer patients given adjuvant goserelin.
Oncology (Williston Park); 2005 Aug; 19(9):1142. PubMed ID: 16402596
[No Abstract] [Full Text] [Related]
19. Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer.
Akaza H
BJU Int; 2004 Jan; 93(1):42-6. PubMed ID: 14678365
[TBL] [Abstract][Full Text] [Related]
20. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]